| Recruiting | Delivering tAN to Reduce HMB: The LUNA Study NCT07326722 | Spark Biomedical, Inc. | N/A |
| Not Yet Recruiting | Effectiveness of an mHealth Innovation on the Impact of Menstrual Complaints in Adolescents NCT07457957 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | N/A |
| Not Yet Recruiting | Evaluating the Reliability and Validity of the Arabic Version of the SAMANTA Questionnaire: A Step Toward Impr NCT07267611 | Assiut University | — |
| Recruiting | Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study NCT05916469 | Oregon Health and Science University | — |
| Completed | Transcutaneous Auricular Neurostimulation as a Treatment for Women With Heavy Menstrual Bleeding: A Dose-findi NCT06814028 | Spark Biomedical, Inc. | N/A |
| Recruiting | Juveena Hydrogel System Feasibility Study for Heavy Menstrual Bleeding (HMB) NCT06634719 | Rejoni Inc. | N/A |
| Recruiting | Hormonal Management of Heavy Menstrual Bleeding in Adolescents NCT06740929 | University Hospital, Geneva | — |
| Not Yet Recruiting | TRanEXamic Acid to Decrease Heavy Menstrual Bleeding in Individuals Anticoagulated for Venous Thromboembolism NCT06452342 | University Health Network, Toronto | Phase 4 |
| Terminated | Identifying the Determinants of Bleeding and Hypermobility in Patients With Heavy Menstrual Bleeding NCT05685199 | St. Jude Children's Research Hospital | — |
| Unknown | Heavy Menstrual Bleeding and Iron Deficiency Anemia NCT05079815 | Assiut University | — |
| Recruiting | Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids NCT06671548 | Qilu Pharmaceutical Co., Ltd. | Phase 3 |
| Completed | Delivering Transcutaneous Auricular Neurostimulation to Reduce Heavy Menstrual Bleeding in Patients With and W NCT06064851 | Five Liters, Inc. | N/A |
| Recruiting | A Registry to Gather Real World Use Data on the Cerene® Cryotherapy Device NCT05922657 | Channel Medsystems | — |
| Active Not Recruiting | Menstrual Complaints in Adolescents and Adults NCT06921629 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | — |
| Active Not Recruiting | Impact of Incomplete Endometrial Ablation NCT06122363 | Maxima Medical Center | — |
| Unknown | IUB SEAD RED (Revolutionary Endometrial Ablation Device Study) NCT05606146 | Ocon Medical Ltd. | N/A |
| Unknown | Efficacy and Safety of BG2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids. NCT05620355 | Bio Genuine (Shanghai) Biotech Co., Ltd. | Phase 3 |
| Completed | A Study Called Champion-HMB to Learn More About Females With Heavy Menstrual Bleeding and Available Treatments NCT05176496 | Bayer | — |
| Terminated | A Study to Assess Patient-Reported Quality of Life and Effectiveness on Control of Bleeding in Adult Participa NCT05026502 | AbbVie | — |
| Unknown | IUB SEAD RED (Revolutionary Endometrial Ablation Device Study NCT04959396 | Ocon Medical Ltd. | N/A |
| Unknown | Myomectomy vs Uterine Artery Embolization vs GnRh Antagonist for AUB-L NCT04856306 | Medstar Health Research Institute | — |
| Completed | Alternate Day Versus Daily Oral Iron Therapy in Adolescents NCT05007899 | Baylor College of Medicine | Phase 4 |
| Completed | Prospective Comparison of Incidence of Heavy Menstrual Bleeding in Women Treated With Direct Oral Anticoagulan NCT04477837 | Cardioangiologisches Centrum Bethanien | — |
| Completed | Minitouch Endometrial Ablation System Treatment for Menorrhagia: An Evaluation of Safety & Effectiveness NCT04267562 | MicroCube, LLC | N/A |
| Unknown | IV Iron vs Oral Iron for Treatment of Anemia in Women With Abnormal Uterine Bleeding NCT04205266 | Thomas Jefferson University | Phase 4 |
| Completed | Ultrasound Evaluation Versus Direct Measurement of Uterine Cavity Length NCT04425577 | Children's Mercy Hospital Kansas City | N/A |
| Withdrawn | Quality of Life Outcomes for Ulipristal Acetate and Tranexamic Acid in the Management of Heavy Menstrual Bleed NCT03027973 | University of Saskatchewan | Phase 1 |
| Terminated | Ulipristal Acetate in Symptomatic Uterine Fibroid NCT04132349 | Mỹ Đức Hospital | Phase 4 |
| Completed | Therapeutic Effect of Herbal Infusion on Menometrorrhagia NCT05406960 | Faculty of Medicine, Sousse | N/A |
| Unknown | Librata Endometrial Ablation Device Treatment to Reduce Menstrual Blood Loss NCT03725306 | LiNA Medical | Phase 3 |
| Unknown | A Clinical Study on Adherence and Efficacy of Different Doses of Active Iron in Treatment Resistant Subjects NCT04778072 | Solvotrin Innovations Ltd | N/A |
| Completed | Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids NCT03317795 | Shannon K. Laughlin-Tommaso | Phase 4 |
| Completed | Treatment of Heavy and/or Prolonged Menstrual Bleeding Without Organic Cause NCT02943655 | Assiut University | Phase 3 |
| Completed | LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Ass NCT03412890 | Myovant Sciences GmbH | Phase 3 |
| Completed | Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of H NCT03271489 | AbbVie | Phase 3 |
| Unknown | Ulipristal Versus Placebo for Women With Bleeding Induced by Mirena NCT03186586 | University of Campinas, Brazil | Phase 4 |
| Completed | LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine NCT03103087 | Myovant Sciences GmbH | Phase 3 |
| Completed | Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids NCT03070951 | ObsEva SA | Phase 3 |
| Completed | LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine NCT03049735 | Myovant Sciences GmbH | Phase 3 |
| Completed | Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids NCT03070899 | ObsEva SA | Phase 3 |
| Completed | Quality of Life in Premenopausal Women With Heavy Menstrual Bleeding NCT03368898 | Bakirkoy Dr. Sadi Konuk Research and Training Hospital | — |
| Unknown | Librata Endometrial Ablation Device Treatment to Reduce Menstrual Blood Loss in Sites Across the United Kingdo NCT02971189 | Birmingham Women's NHS Foundation Trust | N/A |
| Completed | An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual NCT02925494 | AbbVie | Phase 3 |
| Completed | Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heav NCT02691494 | AbbVie | Phase 3 |
| Completed | Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heav NCT02654054 | AbbVie | Phase 3 |
| Unknown | Evaluation of 4th Generation Bipolar Radiofrequency Endometrial Ablation Device NCT02449304 | Birmingham Women's NHS Foundation Trust | Phase 4 |
| Completed | Effectiveness of Truclear on Patient Quality of Life NCT02934789 | All For Women Healthcare, Illinois | N/A |
| Completed | Tranexamic Acid in Adolescents With Heavy Menstrual Bleeding NCT01846507 | Nationwide Children's Hospital | Phase 4 |
| Terminated | HMB- Data Collection Methods NCT02001324 | Women and Infants Hospital of Rhode Island | N/A |
| Completed | Dexamethasone for Excessive Menstruation NCT01769820 | University of Edinburgh | Phase 2 |
| Completed | Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care NCT01431326 | Daniel Benjamin | — |
| Unknown | Pretreatment With Norethindrone Acetate Prior to Levonorgestrel IUS Insertion for Heavy Menstrual Bleeding NCT01391052 | Scott and White Hospital & Clinic | Phase 4 |
| Completed | Therapeutic Equivalence Trial of Two Hormonal-IUDs in Patients With Heavy Menstrual Bleeding NCT01695902 | Uteron Pharma S.A. | Phase 3 |
| Completed | Efficacy and Safety of XP12B in Women With Menorrhagia NCT00401193 | Ferring Pharmaceuticals | Phase 3 |
| Completed | Efficacy and Safety Study of XP12B in Women With Menorrhagia NCT00386308 | Ferring Pharmaceuticals | Phase 3 |
| Completed | Safety Study of XP12B in Women With Menorrhagia NCT00113568 | Ferring Pharmaceuticals | Phase 3 |